In January 2016, the doors were opened to China, one of the largest and fastest growing markets in the world, with the approval of the company’s Foley catheter for infection prevention. The first order comprises 100,000 Bactiguard Infection Protection Foley catheters (BIP Foley). A smaller portion of the order will be delivered this quarter and the bulk in the second quarter of 2016.

“This is a major breakthrough for Bactiguard and we have high expectations on China, a country with big challenges in preventing infections and reducing antibiotic consumption,” says Cecilia Edström, Head of Sales and New Business at Bactiguard.

Bactiguard’s Chinese partner, Jian An Pharmaceuticals (Jian An), is now preparing the launch activities in the country. Jian An has some 2,000 sales representatives and 5,000 hospital customers throughout China.

The order value of more than 3 MSEK will not generate any sales revenue for Bactiguard as the delivery will be made against the market contribution agreed between Bactiguard and Jian An already in 2011.

Healthcare associated infections is a global problem and today the third largest cause of death in the Western world. In China, the problem is rapidly growing and a great challenge. Chinese representatives have expressed a strategy to reduce antibiotic use, which means that extensive efforts to reduce infections are required. Bactiguard’s infection protection solution therefore becomes a natural part of the prevention of healthcare associated infections.

This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 21 January 2016, at 08.00.

For further information, please contact:
Ulrika Berglund, Head of External Affairs, mobile: 46 708 800 407